Lilly May Lead Pharma 3Q EPS Growth As Astra, Merck Fall

Sam Fazeli, Bloomberg Industries


Eli Lilly has had the largest increase in 2013 adjusted consensus EPS estimates across large pharma peers since the start of the third quarter. This was mostly driven by deep cost cutting and better than expected sales from drugs like Cymbalta.

Read more >>> 

Bloomberg BRIEF Newsletters